BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30943322)

  • 1. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.
    Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
    Cytopathology; 2019 Sep; 30(5):510-518. PubMed ID: 30943322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.
    Courtade-Saïdi M; Aziza J; d'Aure D; Bérard E; Evrard S; Basset C; Lacoste-Collin L
    Cytopathology; 2016 Dec; 27(6):456-464. PubMed ID: 27873391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma.
    Piaton E; Carré C; Advenier AS; Decaussin-Petrucci M; Mège-Lechevallier F; Lantier P; Granier G; Ruffion A
    Cancer Cytopathol; 2014 Mar; 122(3):211-20. PubMed ID: 24302621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology.
    Piaton E; Advenier AS; Carré C; Decaussin-Petrucci M; Mege-Lechevallier F; Ruffion A
    Cytopathology; 2013 Oct; 24(5):327-34. PubMed ID: 23003335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
    Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
    Kelly JD; Dudderidge TJ; Wollenschlaeger A; Okoturo O; Burling K; Tulloch F; Halsall I; Prevost T; Prevost AT; Vasconcelos JC; Robson W; Leung HY; Vasdev N; Pickard RS; Williams GH; Stoeber K
    PLoS One; 2012; 7(7):e40305. PubMed ID: 22792272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments.
    Stoeber K; Swinn R; Prevost AT; de Clive-Lowe P; Halsall I; Dilworth SM; Marr J; Turner WH; Bullock N; Doble A; Hales CN; Williams GH
    J Natl Cancer Inst; 2002 Jul; 94(14):1071-9. PubMed ID: 12122098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
    Piaton E; Advenier AS; Carré C; Decaussin-Petrucci M; Mège-Lechevallier F; Hutin K; Nennig C; Colombel M; Ruffion A
    Cancer Cytopathol; 2017 Jul; 125(7):552-562. PubMed ID: 28371465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of bladder cancer with urinary cytology, immunocytology and DNA-image-cytometry.
    Planz B; Synek C; Deix T; Böcking A; Marberger M
    Anal Cell Pathol; 2001; 22(3):103-9. PubMed ID: 11455029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cytopathological factors affecting the cellularity of urinary cell blocks and the implication for diagnosis and follow-up of urinary bladder urothelial carcinoma.
    Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
    Cytopathology; 2018 Dec; 29(6):537-544. PubMed ID: 29873845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
    Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
    Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
    Comploj E; Mian C; Ambrosini-Spaltro A; Dechet C; Palermo S; Trenti E; Lodde M; Horninger W; Pycha A
    Cancer Cytopathol; 2013 Jul; 121(7):392-7. PubMed ID: 23495066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual immunocytochemical staining of annexin A10 and p53 in low-grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology.
    Kobayashi G; Hayashi T; Sentani K; Uraoka N; Shibata J; Nobuhiro R; Saito Y; Ishida K; Kaneko Y; Ikeda K; Hanamoto M; Nose H; Arihiro K; Hinata N; Oue N
    Cancer Cytopathol; 2023 Sep; 131(9):548-560. PubMed ID: 37300383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of urinary cytology in the evaluation of bladder neoplasms.
    Murphy WM
    Hum Pathol; 1990 Sep; 21(9):886-96. PubMed ID: 2203672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquilin2 as a novel marker for detection of urothelial carcinoma cells in urine.
    Shimada K; Fujii T; Tatsumi Y; Anai S; Fujimoto K; Konishi N
    Diagn Cytopathol; 2016 Jan; 44(1):3-9. PubMed ID: 26303000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.